header
Image from OpenLibrary

Low - molecular-weight-heparin versus unfractionated heparin in pregnant women with recurrent abortion associated with antiphospholipid syndrome / Amr Mohammed Abdelaziz ; Supervised Gamal Mohamed Eid , Maha Youssef

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Amr Mohammed Abdelaziz , 2015Description: 105 P. ; 25cmOther title:
  • مقارنة بين الهيبارين قليل الوزن الجزيئى و الهيبارين غير المجزء فى علاج النساء الحوامل المصابات بالاجهاض المتكرر الناتج عن متلازمة مضاد الدهون الفوسفاتية [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Gynecology and Obstetrics Summary: Women with antiphospholipid syndrome (APS) have a spontaneous abortion rate as high as 90% for pregnancies without pharmacologic treatment. APS is strongly correlated with recurrent abortion and pregnancy complications such as intrauterine growth restriction (IUGR), preterm labor, preeclampsia, and intrauterine fetal death (IUFD). The adverse effects of antiphospholipid antibodies on trophoblast differentiation and invasion, placental infarctions, and thrombosis are thought to be responsible for recurrent abortion and pregnancy complications associated with APS. During the past 27 years, several treatments such as unfractionated heparin (UFH), low molecular weight heparin (LMWH), plasmapharesis, moderate to high dose prednisone, intravenous immunoglobulin, and low dose aspirin (LDA) have been used in the management of pregnant women with history of recurrent pregnancy loss secondary to APS. A meta-analysis of 13 randomized controlled trails of various management options for pregnant women with a history of recurrent abortion secondary to APS found that combined UFH and LDA was the best management potion, reducing pregnancy loss by 54%
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Date due Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.15.M.Sc.2015.Am.L (Browse shelf(Opens below)) Not for loan 01010110067323000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.15.M.Sc.2015.Am.L (Browse shelf(Opens below)) 67323.CD Not for loan 01020110067323000

Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Gynecology and Obstetrics

Women with antiphospholipid syndrome (APS) have a spontaneous abortion rate as high as 90% for pregnancies without pharmacologic treatment. APS is strongly correlated with recurrent abortion and pregnancy complications such as intrauterine growth restriction (IUGR), preterm labor, preeclampsia, and intrauterine fetal death (IUFD). The adverse effects of antiphospholipid antibodies on trophoblast differentiation and invasion, placental infarctions, and thrombosis are thought to be responsible for recurrent abortion and pregnancy complications associated with APS. During the past 27 years, several treatments such as unfractionated heparin (UFH), low molecular weight heparin (LMWH), plasmapharesis, moderate to high dose prednisone, intravenous immunoglobulin, and low dose aspirin (LDA) have been used in the management of pregnant women with history of recurrent pregnancy loss secondary to APS. A meta-analysis of 13 randomized controlled trails of various management options for pregnant women with a history of recurrent abortion secondary to APS found that combined UFH and LDA was the best management potion, reducing pregnancy loss by 54%

Issued also as CD

There are no comments on this title.

to post a comment.